DNAprint Genomics (DNAG)

[SlopsterSlasher]

The next market for genomics-based products is DNAPrint's pharmacogenomics market. This market is also known as the "personalization of medicine" market, part of the molecular diagnostics market identified above. DNAP's product
pipeline includes OVANOME, STATNOME, and others that classify a patient's genetic characteristics and their potential response to drugs. DNAPrint may also participate in the pharmaceutical company expansion into genomics by partnering its ADMIXMAP platform, and/or sharing with the pharmaceutical industry new drug targets/indications that are discovered in house. DNAPrint also expects to enter into collaborations with leading pharmaceutical companies to conduct pre-clinical pharmacogenomics research on new drugs in their pipelines.

From - 10ksb filing date 4-15-03
Part 1
overview of the Market
# 14